MercachemSyncom changes name to Symeres - Gilde Healthcare

MercachemSyncom changes name to Symeres

November 19, 2020

MercachemSyncom changes name to Symeres

Nijmegen (The Netherlands) – MercachemSyncom today announced that it will change its name and operate under the registered trade name of Symeres.
 
The new name reflects the strategic evolution of the company, with the growth of integrated drug discovery and development services, which complement the company’s strong reputation in synthetic discovery and development chemistry. Recent examples of this evolution include the acquisition of ADME-Tox provider Admescope in November 2020 and strategic alliances integrating our services with high-quality CROs in the fields of in vitro biology, biophysics, and structural biology.
 
The name Symeres (derived from Sy-ncom Me-rcachem res-research) and accompanying tagline “making molecules matter” are derived from the experience and success of the Syncom and Mercachem legacy organizations and their core strengths in innovative research.
 
Dr. Eelco Ebbers, CEO of Symeres, added,

“The evolution of MercachemSyncom into Symeres is representative of the continuing expansion of the organization and our move into integrated solutions for drug discovery and development services, alongside our strong chemistry-centric services. The most recent example being our acquisition of Admescope. We look forward to continuing our journey with our clients around the world under our new identity, without forgetting the core values of quality, integrity, transparency, and innovation that got us to where we are today.”

For further information, please contact:
Dr. Russell Thomas
Head of Business Development
Symeres
Email: russell.thomas@symeres.com

 

About Symeres
Symeres, formerly MercachemSyncom, is the leading mid-sized European contract research organization offering innovative chemistry, medicinal chemistry, ADME, early process research services, and GMP production to accelerate the drug discovery and development process in a flexible and cost-effective way. Symeres also offers integrated drug-discovery services from hit to clinic via multiple-platform strategic alliances under a single MSA. Working for many pharmaceutical and biotech companies throughout the world, Symeres is recognized for its high-quality products and services and its unprecedented problem-solving capabilities.
For more information, please visit: www.symeres.com.

About Gilde Healthcare
Gilde Healthcare is a specialized healthcare investor managing over €1.4 billion ($1.5 billion) across two fund strategies: venture & growth capital and private equity. Gilde Healthcare’s venture & growth capital fund invests in fast growing companies active in digital health, medtech and therapeutics. The venture & growth companies are based in Europe and North America. Gilde Healthcare’s private equity fund invests in profitable European lower mid-market healthcare companies with a focus on the Benelux and DACH region. The private equity fund targets healthcare providers, suppliers of medical products and service providers in the healthcare market. For more information, visit the company’s website at www.gildehealthcare.com.

Gilde Healthcare Adcendo Completes $135 Million Series B to Advance First- in-class ADC Pipeline

Financing led by TCGX, including new investment from TPG, Orbimed Advisors, Venrock Healthcare Capital Partners, Surveyor Capital (a Citadel company), and Logos Capital, with participation from all existing investors Proceeds will be used to support...
November 25, 2024

Gilde Healthcare portfolio company Levicept Presents Positive Phase II Data for Novel Neurotrophin-3 Inhibitor, LEVI-04 at ACR Convergence 2024

Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for osteoarthritis, is presenting the results from its positive Phase II trial of LEVI-04 at the American College of Rheumatology's annual...
November 14, 2024

Gilde Healthcare company Noema Pharma Announces First Patients Dosed in Phase 2b Study for Tourette Syndrome

Phase 2b study will evaluate the safety and efficacy of gemlapodect (NOE-105) in patients with Tourette syndrome Noema Pharma AG, a clinical-stage neuroscience-based company, today announced the first patients have been dosed in a global...
October 30, 2024